The correlation between heavy metal ions in blood and metabolic dysfunction-associated steatotic liver disease from 1999 to 2018 based on NHANES data DOI Creative Commons
Haijun Ma,

Ju Zhao,

Jian Xu

et al.

Frontiers in Public Health, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 7, 2025

Metabolic-associated steatohepatitis and liver fibrosis (MASLD) is a growing public health concern, with environmental factors potentially playing role in its development. This study aimed to investigate the associations between serum cadmium mercury levels risk of MASLD nationally representative sample from United States. Data National Health Nutrition Examination Survey 1999 2018 were analyzed. Serum concentrations measured, was defined based on established criteria. Logistic regression models used assess metal MASLD, adjustments for potential confounders. Stratified analyses restricted cubic spline curves employed examine subgroup differences nonlinear relationships. The revealed significant inverse likelihood MASLD. Individuals highest quartiles had lower odds compared those lowest (Model 3: Cadmium Q4 vs. Q1, Mercury Q1). showed stronger older adults, males, never smokers cadmium, females individuals without diabetes mercury. Nonlinear dose-response indicated critical thresholds beyond which dynamics changed. Higher associated notable variations across subgroups. These findings challenge conventional understanding these heavy metals as universally harmful highlight need further research unravel complex interplay exposures pathophysiology.

Language: Английский

The first MASH drug therapy on the horizon: Current perspectives of resmetirom DOI Creative Commons
Salvatore Petta, Giovanni Targher, Stefano Romeo

et al.

Liver International, Journal Year: 2024, Volume and Issue: 44(7), P. 1526 - 1536

Published: April 5, 2024

Abstract The rising prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) poses a significant global health challenge, affecting over 30% adults worldwide. MASLD is linked to increased mortality rates and substantial healthcare costs, primarily driven by its progression steatohepatitis (MASH), which can lead severe complications including cirrhosis hepatocellular carcinoma. Despite growing burden, effective pharmacotherapy for MASLD/MASH has been lacking until the recent conditional approval resmetirom FDA. Resmetirom, liver‐targeted thyroid hormone receptor‐β selective drug, shown promise in clinical trials treating non‐cirrhotic MASH with moderate advanced fibrosis. It demonstrated efficacy reducing hepatic fat content, improving histology (both resolution fibrosis improvement), ameliorating biomarkers damage without effects on body weight or glucose metabolism. Notably, also exhibits favourable circulating lipids, potentially cardiovascular risk patients. safety profile appears acceptable, gastrointestinal adverse events being most common, though generally mild moderate. However, long‐term surveillance warranted monitor potential risks related thyroid, gonadal, bone diseases. Clinical implementation faces challenges patient selection monitoring treatment response, will heavily rely non‐invasive tests assessment. Nonetheless, represents landmark breakthrough treatment, paving way future therapeutic strategies aiming mitigate multifaceted associated this complex disease.

Language: Английский

Citations

63
Rutin ameliorated lipid metabolism dysfunction of diabetic NAFLD via AMPK/SREBP1 pathway DOI
Yadi Liu,

Zhongyan Sun,

Ruixue Dong

et al.

Phytomedicine, Journal Year: 2024, Volume and Issue: 126, P. 155437 - 155437

Published: Feb. 9, 2024

Language: Английский

Citations

52
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease DOI Creative Commons
Zobair M. Younossi,

Markos Kalligeros,

Linda Henry

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 19, 2024

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does prevalence metabolic dysfunction associated steatotic liver disease (MASLD). Currently, 38% all adults 7-14% children adolescents have MASLD. By 2040, MASLD rate for is projected over 55%. Although many with will not develop progressive disease, given vast number patients MASLD, it has now become top indication transplant in United States those hepatocellular carcinoma (HCC) women. However, most common cause mortality among remains death cardiovascular diseases. In addition outcomes (cirrhosis HCC), increased risk developing de-novo T2D, chronic kidney sarcopenia extrahepatic cancers. Furthermore, decreased health related quality life, work productivity, fatigue healthcare resource utilization substantial economic burden. Similar other lifestyle interventions heathy diet physical activity remain cornerstone managing these patients. a T2D drugs are available treat co-morbid Resmetirom only MASH-targeted medication that was recently approved by Federal Drug Administration use stage 2-3 fibrosis. The following review provides an overview epidemiology, its factors demonstrates without further global initiatives, may increase.

Language: Английский

Citations

44
What defines a healthy gut microbiome? DOI
Matthias Van Hul, Patrice D. Cani, Camille Petitfils

et al.

Gut, Journal Year: 2024, Volume and Issue: 73(11), P. 1893 - 1908

Published: Sept. 25, 2024

The understanding that changes in microbiome composition can influence chronic human diseases and the efficiency of therapies has driven efforts to develop microbiota-centred such as first next generation probiotics, prebiotics postbiotics, microbiota editing faecal transplantation. Central research is how disease impacts vice versa, yet there a problematic issue with term 'dysbiosis', which broadly links microbial imbalances various illnesses without precision or definition. Another significant discussions defining 'healthy individuals' ascertain what characterises healthy microbiome. This involves questioning who represents healthiest segment our population-whether it those free from illnesses, athletes at peak performance, individuals living healthily through regular exercise good nutrition even elderly adults centenarians have been tested by time achieved remarkable longevity.This review advocates for delineating 'what defines microbiome?' considering broader range factors related health environmental influences on microbiota. A undoubtedly linked gut health. Nevertheless, very difficult pinpoint universally accepted definition 'gut health' due complexities measuring functionality besides composition. We must take into account individual variabilities, diet, lifestyle, host factors. Moreover, challenge distinguishing causation correlation between overall presented.The also highlights resource-heavy nature comprehensive assessments, hinders their practicality broad application. Finally, we call continued nuanced approach better understand intricate evolving concept health, emphasising need more precise inclusive definitions methodologies studying

Language: Английский

Citations

42
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases DOI Creative Commons

Reddemma Sandireddy,

Suganya Sakthivel,

Priyanka Gupta

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: July 16, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), is the most common disorder worldwide, with an estimated global prevalence of more than 31%. steatohepatitis (MASH), formerly (NASH), a progressive form MASLD characterized by hepatic steatosis, inflammation, and fibrosis. This review aims to provide comprehensive analysis extrahepatic manifestations MASH, focusing on chronic diseases related cardiovascular, muscular, renal systems. A systematic published studies literature was conducted summarize findings systemic impacts MASH. The focused association MASH metabolic comorbidities, cardiovascular mortality, sarcopenia, kidney disease. Mechanistic insights into concept lipotoxic inflammatory "spill over" from MASH-affected were also explored. are highly associated (50%-80%) other comorbidities such impaired insulin response, type 2 diabetes, dyslipidemia, hypertriglyceridemia, hypertension. Furthermore, 90% obese patients diabetes have Data suggest that in middle-aged individuals (especially those aged 45-54), independent risk factor for plays crucial role mediating pathological effects observed. Understanding multifaceted impact heart, muscle, early detection stratification. knowledge timely implementing management strategies addressing multi-organ involvement pathogenesis.

Language: Английский

Citations

24
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options DOI Open Access
Piero Portincasa, Mohamad Khalil, Laura Mahdi

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 5640 - 5640

Published: May 22, 2024

The epidemiological burden of liver steatosis associated with metabolic diseases is continuously growing worldwide and in all age classes. This condition generates possible progression damage (i.e., inflammation, fibrosis, cirrhosis, hepatocellular carcinoma) but also independently increases the risk cardio-metabolic cancer. In recent years, terminological evolution from “nonalcoholic fatty disease” (NAFLD) to “metabolic dysfunction-associated (MAFLD) and, finally, steatotic (MASLD) has been paralleled by increased knowledge mechanisms linking local hepatic) systemic pathogenic pathways. As a consequence, need for an appropriate classification individual phenotypes oriented investigation innovative therapeutic tools. Besides well-known role lifestyle change, number pharmacological approaches have explored, ranging antidiabetic drugs agonists acting on gut–liver axis at level (mainly farnesoid X receptor (FXR) agonists, PPAR thyroid hormone agonists), anti-fibrotic anti-inflammatory agents. intrinsically complex pathophysiological history MASLD makes selection single effective treatment major challenge, so far. this evolving scenario, cooperation between different stakeholders (including subjects risk, health professionals, pharmaceutical industries) could significantly improve management disease implementation primary secondary prevention measures. high healthcare search new, effective, safe pressing need, together accurate characterization phenotypes. Recent promising advances indicate that we may soon enter era precise personalized therapy MASLD/MASH.

Language: Английский

Citations

19
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease DOI
Xiaodong Zhou, Seung Up Kim, Terry Cheuk‐Fung Yip

et al.

Gut, Journal Year: 2024, Volume and Issue: 73(11), P. 1883 - 1892

Published: Aug. 1, 2024

Background Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD). Aim To explore the effects of statins on long-term risk all-cause mortality, liver-related clinical events (LREs) and stiffness progression MASLD. Methods This cohort study collected data MASLD undergoing at least two vibration-controlled transient elastography examinations 16 tertiary referral centres. Cox regression analysis was performed to examine association between statin usage mortality LREs stratified by compensated advanced chronic (cACLD): baseline measurement (LSM) ≥10 kPa. Liver defined as an LSM increase ≥20% for cACLD from <10 kPa or non-cACLD. reduction decrease cACLD. Results We followed up 7988 5.9 (IQR 4.6–8.2) a median 4.6 years. At baseline, 40.5% used statins, present 17%. Statin significantly associated lower (adjusted HR=0.233; 95% CI 0.127 0.426) HR=0.380; 0.268 0.539). also rates (HR=0.542; 0.389 0.755) non-cACLD HR=0.450; 0.342 0.592), but not HR=0.914; 0.778 1.074). Conclusions relatively

Language: Английский

Citations

19
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment DOI Creative Commons
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Citations

19
Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease DOI Creative Commons
Min Yu, Xiaoyuan Wei,

Zhigong Wei

et al.

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: June 1, 2024

Abstract Backgrounds Insulin resistance (IR) plays a vital role in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). However, it remains unclear whether triglyceride–glucose (TyG) related parameters, which serve as useful biomarkers to assess IR, have prognostic effects on mortality outcomes MASLD. Methods Participants National Health and Nutrition Examination Survey (NHANES) database from 1999 2018 years were included. TyG its parameters [TyG-waist circumference (TyG-WC) TyG-waist height ratio (TyG-WHtR)] calculated. Kaplan–Meier curves, Cox regression analysis, restricted cubic splines (RCS) conducted evaluate association between TyG-related indices with all-cause cardiovascular adults The concordance index (C-index) was used prediction accuracy indices. Results A total 8208 (4209 men 3999 women, median age 49.00 years) MASLD included this study. Multivariate-adjusted analysis revealed that high quartile levels significantly associated participants [ adjusted hazard (aHR) = 1.25, 95% confidence interval (CI) 1.05–1.50, P 0.014; TyG-WC aHR for 1.28, CI 1.07–1.52, 0.006; TyG-WHtR 1.50, 1.25–1.80, < 0.001; 1.81, 1.28–2.55, 2.22, 1.55–3.17, 0.001]. C-index predicting 0.563 index, 0.579 0.585 respectively. Regarding mortality, 0.561 0.607 0.615 Nonlinear trends observed ( 0.001 0.012, respectively). non-linear relationship 0.025). Subgroup suggested aged 65 old those without comorbidities more sensitive Conclusion Findings study highlight predictive value indices, especially would be surrogate clinical management

Language: Английский

Citations

17
Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System DOI
Antonis A. Manolis, Theodora A. Manolis, Apostolos Vouliotis

et al.

Trends in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

4